Synthetic Biologics Inc (SYN)

1.70
AMEX : Health Care
Prev Close 1.66
Day Low/High 1.66 / 1.73
52 Wk Low/High 0.93 / 3.45
Avg Volume 709.60K
Exchange AMEX
Shares Outstanding 90.83M
Market Cap 150.77M
EPS -0.50
P/E Ratio 2.81
Div & Yield N.A. (N.A)

Latest News

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients --

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials --

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

-- SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

-- Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs --

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

-- Appointment Reflects Company's Late-Stage Clinical Focus and Plans to Prepare for Commercialization --

Synthetic Biologics To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016

Synthetic Biologics To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016

-- Conference Call Scheduled for Thursday, May 5, 2016 at 4:30 p.m. EDT --

Synthetic Biologics To Report 2015 Year End Results On March 10, 2016

Synthetic Biologics To Report 2015 Year End Results On March 10, 2016

-- Conference Call Scheduled for Thursday, March 10, 2016 at 4:30 p.m. EST --

Synthetic Biologics Reports Results Of Independent Third Party Evaluations Of Trimesta™ Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis

Synthetic Biologics Reports Results Of Independent Third Party Evaluations Of Trimesta™ Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis

-- Data Analysis Did Not Demonstrate Statistically Significant Differences Between Treatment and Placebo Groups --

Synthetic Biologics Reports Positive Topline Data From Second Phase 2 Clinical Trial Of SYN-010 In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Reports Positive Topline Data From Second Phase 2 Clinical Trial Of SYN-010 In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

-- SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients --

Synthetic Biologics Targeting IBS Cause, Not Just Treatment

Synthetic Biologics Targeting IBS Cause, Not Just Treatment

Shares of Synthetic Biologics are up 65% so far in 2015, due to high expectations for its 2016 gastrointestinal drugs.

2016 Will Be Big in Battle Against IBS Says Synthetic Biologics CEO

2016 Will Be Big in Battle Against IBS Says Synthetic Biologics CEO

Shares of Synthetic Biologics (SYN) are up 65% so far in 2015 due to high expectations for its gastrointestinal drugs.

Synthetic Biologics To Webcast Microbiome Clinical Program Seminar

Synthetic Biologics To Webcast Microbiome Clinical Program Seminar

-- Event to Feature Company's Two Phase 2 Clinical Programs for Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection --

Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection

Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection

-- SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --

Synthetic Biologics To Host Microbiome Clinical Program Seminar In New York City

Synthetic Biologics To Host Microbiome Clinical Program Seminar In New York City

-- Event to Highlight Company's Two Phase 2 Clinical Programs: Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection --

Grant Awarded To Synthetic Biologics' Academic Collaborator To Fund Further Evaluation Of Monoclonal Antibody For The Prevention Of Whooping Cough (Pertussis)

Grant Awarded To Synthetic Biologics' Academic Collaborator To Fund Further Evaluation Of Monoclonal Antibody For The Prevention Of Whooping Cough (Pertussis)

-- The University of Texas at Austin Receives Grant from the Bill & Melinda Gates Foundation --

Synthetic Biologics' Novel Irritable Bowel Syndrome With Constipation (IBS-C) Program Featured In American College Of Gastroenterology Poster

Synthetic Biologics' Novel Irritable Bowel Syndrome With Constipation (IBS-C) Program Featured In American College Of Gastroenterology Poster

-- Company's SYN-010 Program to Reduce the Impact of Methane Gas in the Gut Currently in Phase 2 Clinical Trials --

Synthetic Biologics To Report Third Quarter Results On November 5, 2015

Synthetic Biologics To Report Third Quarter Results On November 5, 2015

-- Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST --